The information provided herein is accurate, updated and complete as per the best practices of the Company. Please note that this information should not be treated as a replacement for physical medical consultation or advice. We do not guarantee the accuracy and the completeness of the information so provided. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company. We do not take any responsibility for the consequences arising out of the aforementioned information and strongly recommend you for a physical consultation in case of any queries or doubts.
Dyslipidemia, Hypertriglyceridaemin, Prophylaxis of myocardial infarction
Administration
Should be taken with food.
Adult Dose
Oral
Hypertriglyceridaemia
Adult: 4 g once daily 2g twice daily.
Secondary prophylaxis of myocardial infarction
Adult: 1 g daily.
Child Dose
<18 years: Safety and efficacy not established
Contraindication
Patients with known hypersensitivity (e.g., anaphylactic reaction) to LOVAZA or any of its components.
Mode of Action
The omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid are long-chain n-3 polyunsaturated fatty acids, which compete with arachidonic acid for inclusion in cyclo-oxygenase and lipoxygenase pathways. Their actions include hypolipidaemic action (especially a reduction in plasma triglycerides) by reducing very-low-density lipoproteins; anti-inflammatory action, attributed to effects on leukotriene synthesis; and antiplatelet effect, attributed to effects on prostanoid synthesis, which promote vasodilatation, reduction in platelet aggregation, increased bleeding time and decreased platelet counts.
Precaution
Haemorrhagic disorders or those receiving anticoagulants or other drugs that have antithrombotic activity; asthmatic patients sensitive to aspirin. Monitor hepatic function in patients with hepatic impairment, especially if receiving high doses.
Lactation: Not known if excreted in breast milk; use caution
